Atopic Dermatitis (AD)
Conditions
Brief summary
A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision. The product was applied twice daily, and efficacy was assessed through dermatological scoring, instrumental measurements, and subjective questionnaires. Results aimed to show improvements in barrier function, hydration, skin texture, and reduction of erythema, dryness, and pruritus, with feedback on comfort and quality of life.
Interventions
OTHERNovel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.
Apply twice a day on the affected skin area to protect it, previously cleaned and dried. No rinsing is required. Volunteers were instructed not to use any other cosmetic product in the study area until the end of the study.
Sponsors
Centro Médico Complutense Grupo Virtus
i+Med S.Coop.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Sex: both. * Age: from 0 months onwards (includes children and adults). * Atopic-prone skin. * Mild to moderate flare-up. * Skin dryness. * Signed informed consent (by the volunteer or legal guardian as applicable). * Adequate understanding of the clinical study by the participant or legal guardian. * Good physical and psychological health. * No application of any product on the experimental area on the first day of the trial. * Availability to guarantee visits to the research center.
Exclusion criteria
* History of allergies to cosmetic products. * Recent surgery or treatments in the study area. * Oncology patients. * Use of antihistamines and antibiotics within 15 days prior to the start of the study. * Treatment with antihistamines, antibiotics, corticosteroids, immunosuppressants or completion of such treatment within 15 days prior to the start of the study. * Use of any other product for dermatitis during the study. * Sun exposure or UVA rays during the study. * Participation in another clinical study. * Health problems that may compromise adherence to the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SCORAD (SCORing Atopic Dermatitis) Index | 56 days | The assessment with the SCORAD index included lesion extent and the intensity of objective parameters such as erythema, edema/papules, exudation/crusting, lichenification, excoriation, and dryness, as well as subjective symptoms including pruritus and sleep disturbance. The scale evaluates symptoms from 0 (no signs) to 3 (severe). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biometric Analysis | 56 days | Using Mexameter® MX 18 probe anti-erythema efficacy was determined by measuring the light reflected by the skin . |
| Subjective evaluation | 56 days | In adult participants, quality of life was assessed using the validated Dermatology Life Quality Index (DLQI) questionnaire. The DLQI consists of 10 items covering symptoms, daily activities, leisure, work/school, personal relationships, and treatment. |
| Adverse events record | 28 and 56 days | Adverse events record |
| Tolerance evaluation | 56 days | At the end of the study, the dermatologist assessed local tolerance based on the presence and intensity (mild, moderate, severe) of erythema, xerosis/desquamation, oedema, exudation, comedogenicity, and pigmentation alterations. Causality was also rated according to the scale: not related, improbable, possible, probable, certain, or not assessable. |
Countries
Spain
Outcome results
None listed